Latest: FDA Approves New Biosimilar for Oncology Treatment

Semaglutide, Tirzepatide Linked to Small Increase in Eye Disorder Risk

There is a low but increased risk of optic nerve disorders in patients with type 2 diabetes prescribed semaglutide or tirzepatide, according to a large cohort study.
Tags:
📢

Advertisement

300x250 Banner

Recent Content

COPD Biologics: Early Treatment Insights

Pulmonology • 2 hours ago

Antihypertensive Medication Guidelines

Cardiology • 4 hours ago

Juvenile Arthritis Care Transition

Rheumatology • 6 hours ago